文献速递消化系统肿瘤

早发性与晚发性散发性结直肠癌预后比较:系统综述与荟萃分析

Prognosis of early-onset versus late-onset sporadic colorectal cancer: Systematic review and meta-analysis.
PubMed 文献 · Eur J Cancer · 2024-12-07

系统综述与荟萃分析纳入26项研究、1,062,037例患者分析分期分布、567,689例纳入预后分析,比较早发性(<50岁)与晚发性(>50岁)散发性结直肠癌。早发性组诊断时晚期(III-IV期)比例高于晚发性组(60% vs 49%,RR 1.26),但总生存优于晚发性组(HR 0.89),肿瘤特异性生存、无病生存、局部复发和远处复发风险两组无显著差异。

要点

  • 早发性结直肠癌诊断时III-IV期比例高于晚发性(60% vs 49%,RR 1.26,95%CI 1.19-1.35)。
  • 早发性组总生存优于晚发性组(HR 0.89,95%CI 0.81-0.99),但肿瘤特异性生存无显著差异(HR 0.94,95%CI 0.83-1.06)。
  • 无病生存、局部复发和远处复发风险两组无显著差异;早发性直肠癌亚组无病生存较差(HR 1.14,95%CI 1.00-1.30)。

核心结论

  • 尽管现有研究异质性高,早发性结直肠癌患者诊断时分期显著更晚,但肿瘤相关生存无显著差异。
  • 作者认为亟需提高对年轻患者结直肠癌早期检测的警惕性。

研究设计与样本

  • 系统综述与荟萃分析,检索EMBASE-Medline、PubMed和Cochrane Library(2024年3月),纳入比较早发性(<50岁)与晚发性(>50岁)结直肠癌预后且每组至少50例、随访至少1年的研究。
  • 共纳入26项研究;1,062,037例患者纳入分期分布分析(早发性13.4%、晚发性86.6%),567,689例纳入预后荟萃分析;采用ROBINS-E工具评估偏倚风险,PROSPERO注册号CRD42024573264。

主要发现

  • 早发性组60%诊断时为晚期(III-IV期),晚发性组49%(RR 1.26,95%CI 1.19-1.35,I²=87%)。
  • 早发性组总生存优于晚发性组(HR 0.89,95%CI 0.81-0.99,I²=89%)。
  • 肿瘤特异性生存两组无显著差异(HR 0.94,95%CI 0.83-1.06,I²=82%)。
  • 无病生存(HR 1.05,95%CI 0.94-1.16,I²=76%)、局部复发(HR 1.41,95%CI 0.62-3.18,I²=49%)和远处复发(HR 1.51,95%CI 0.79-2.89)风险两组无显著差异。
  • 荟萃回归分析显示早发性直肠癌亚组无病生存较差(HR 1.14,95%CI 1.00-1.30,I²=0%)。

关键数值与推荐

  • 早发性结直肠癌定义为<50岁,晚发性定义为>50岁;纳入研究每组至少50例、随访至少1年。
  • 分期分布分析纳入1,062,037例(早发性13.4%、晚发性86.6%),预后荟萃分析纳入567,689例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出现有研究存在高度异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the last years, a dramatic increase in colorectal cancer (CRC) diagnoses in early-onset (EO) patients has been observed. The prognosis of EO-CRC compared to late-onset (LO) patients is still unclear. This meta-analysis aims to clarify whether there is any difference in the prognosis between the two groups. METHODS: A systematic review was conducted on EMBASE-Medline, Pubmed and Cochrane Library in March 2024 to identify studies comparing overall survival (OS), cancer-specific survival (CSS), disease-free survival (DFS), local recurrence (LR) and distant recurrence (DR) risk outcomes between EO-CRC (<50 years old) and LO-CRC (>50 years old) with at least 50 patients per group and one year of follow-up. The risk of bias was assessed with the ROBINS-E tool. Data from stage prevalence and survival were extracted and meta-analysed. Meta-regression was used to identify impacting effect modifiers. The PROSPERO registration number was CRD42024573264. RESULTS: Twenty-six studies were identified; 1,062,037 patients (13.4% EO-CRC and 86.6% LO-CRC) were included in the stage prevalence and 567,689 in the prognostic meta-analysis. Overall, 60% of the EO-CRC and 49% of the LO-CRC were diagnosed with an advanced stage (III-IV) of disease (RR 1.26, 95%CI 1.19-1.35, I2=87%). EO-CRC had a better OS than LO-CRC (HR 0.89, 95%CI 0.81-0.99, I2=89%) but equal CSS (HR 0.94, 95%CI 0.83-1.06, I2=82%), DFS (HR 1.05 95%CI 0.94-1.16, I2=76%), LR (HR 1.41, 95%CI 0.62-3.18, I2=49%) and DR (HR 1.51, 95%CI 0.79-2.89) risk. Meta-regression analysis identified a worse DFS in the EO-CRC rectal cancer subgroup (HR 1.14, 95%CI 1.00-1.30, I2=0%). CONCLUSIONS: Despite the high heterogeneity of existing studies, EO-CRC patients are diagnosed with significantly more advanced stages than LO-CRC, although this is not reflected in any difference in cancer-related survival. There is an urgent need for increased vigilance in the early detection of CRC in young patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Carbone F, Spinelli A, Ciardiello D, et al. Prognosis of early-onset versus late-onset sporadic colorectal cancer: Systematic review and meta-analysis. Eur J Cancer. 2024. PMID: 39681013. doi:10.1016/j.ejca.2024.115172

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。